EDAP Expands U.S. ENLIGHT Clinical Trial Team to Accelerate Patient Enrollment

U.S. Urologist Dr. Douglas Chinn Named Clinical Instructor

First Ablatherm-HIFU Patient Treated At
Memorial Sloan-Kettering Cancer Center
LYON, France, July 13, 2009 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the
global leader in therapeutic ultrasound, announced today that it has retained
Douglas Chinn, MD to assist and support U.S. investigational sites in enrolling,
treating, and following patients in the U.S. ENLIGHT clinical trial. Dr. Chinn
will work with the current team of expert advisers to liaise between EDAP and
participating physicians in the trial.

Dr. Chinn has a proven track record in bringing minimally invasive prostate
cancer treatment technologies to market. He is globally recognized for his
pioneering role in technical development, clinical implantation and physician
training. He has published several papers and presented at medical congresses
throughout the world on the topic of minimally invasive therapies. Dr. Chinn
also holds several patents pertaining to minimally invasive ablative therapy.

Dr. Chinn earned his medical degree and graduated Phi Beta Kappa with a
bachelor's degree in Biological Sciences at the University of Southern
California (USC). He completed a surgical rotating internship, served as an
Emergency Room Physician, and received urological training at LAC-USC Medical
Center (LA County Hospital). After completing his residency, Dr. Chinn joined
the family urology practice. He became board certified in 1985 and has been
recertified twice since then.

In addition, EDAP is very pleased to announce that Memorial Sloan-Kettering
Cancer Center in New York City has successfully completed its first
Ablatherm-HIFU treatment at the center. The procedure was performed by Dr. James
A. Eastham, MD, Chief Urology Service and proctored by Dr. William Orovan from
Toronto, Canada.

Dr. Chinn commented, "I am very excited to assist with the ENLIGHT clinical
trial and work with EDAP to introduce Ablatherm-HIFU therapy as a minimally
invasive treatment option to the U.S. market. The HIFU technology represents a
major breakthrough for treating patients with prostate cancer. I plan to
leverage my experience in developing and conducting training programs for novel
prostate cancer therapies and to work with many of the top prostate cancer
institutions, including Memorial Sloan-Kettering that is currently participating
in the trial."

Dr. John Rewcastle, Medical Director of EDAP, added, "I am pleased to welcome
Dr. Chinn as a valuable member on our U.S. clinical team. He will work closely
with physicians at investigational sites as part of EDAP's continuing medical
education program. Dr. Chinn has more in depth Ablatherm experience than any
physician in the United States, having worked with Ablatherm experts in
Regensburg, Germany and Toronto, Canada. He has treated and followed a large
number of patients treated with the Ablatherm, and his experience and prior
success in training and working with physicians to adopt technologies will
positively impact our patient accrual efforts."

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically
proven choice for high-intensity focused ultrasound (HIFU) treatment of
localized prostate cancer. HIFU treatment is shown to be a minimally invasive
and effective treatment option with a low occurrence of side effects.
Ablatherm-HIFU is generally recommended for patients with localized prostate
cancer (stages T1-T2) who are not candidates for surgery or who prefer an
alternative option, or for patients who failed radiotherapy treatment. Approved
in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity
Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S.
Phase II/III clinical trial under an Investigational Device Exemption granted by
the FDA, the ENLIGHT U.S. clinical study. The Company also is developing this
technology for the potential treatment of certain other types of tumors. EDAP
TMS SA also produces and commercializes medical equipment for treatment of
urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For
more information on the company, please visit http://www.edap-tms.com,
http://www.hifu-planet.com and http://www.pcaresearch.com.

Forward-Looking Statements

In addition to historical information, this press release contains
forward-looking statements that involve risks and uncertainties. These include
statements regarding the company's growth and expansion plans. Such statements
are based on management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ materially
from those described in these forward-looking statements. Factors that may cause
such a difference include, but are not limited to, those described in the
company's filings with the Securities and Exchange Commission. Ablatherm-HIFU
treatment is in clinical trials, but not FDA-approved or marketed in the United
States.

-0-
CONTACT: EDAP TMS SA
Investor Relations / Legal Affairs
Blandine Confort
+33 4 72 15 31 72
bconfort@edap-tms.com

The Ruth Group
Investors:
R.J. Pellegrino
646-536-7009
rpellegrino@theruthgroup.com
Nick Laudico
646-536-7030
nlaudico@theruthgroup.com